Group 1 - A total of 4,397 listed companies received institutional research, with 1.29 million research activities conducted in the first half of the year, involving 139,900 institutions, an increase of 154 companies compared to the same period last year [2][3] - The mechanical equipment, electronics, and pharmaceutical biology sectors emerged as the primary focus areas for institutional research, with over 400 companies in each sector being investigated [3][4] - The mechanical equipment sector had the highest attention, with 509 companies researched 1,760 times, while the electronics and pharmaceutical biology sectors followed closely with 1,465 and 1,214 research activities, respectively [3][4] Group 2 - 汇川技术 (300124.SZ) was the most favored company, attracting 1,170 institutional research participants, while 美瑞医疗 (300760.SZ) also garnered significant attention with 643 institutions participating in its research [4][5] - The recent focus remains on technology and innovative pharmaceuticals, with companies like 怡合达 (301029.SZ), 乐鑫科技 (688018.SH), and 迈威生物-U (688062.SH) drawing over 200 institutional participants each [5] - Over 70% of the companies that received institutional research in the first half of the year saw their stock prices rise, with 117 stocks experiencing a doubling in price [6] Group 3 - The market is expected to maintain a high-level oscillation pattern, with institutional investors focusing on sectors with long-term industry trends and potential for profit improvement [6][7] - The pharmaceutical sector, particularly innovative drugs, is viewed as having strong certainty and potential for growth, with ongoing recovery in valuation and fundamentals [8] - Institutions are advised to differentiate between genuine innovations and misleading claims in the pharmaceutical sector, emphasizing the importance of companies' ability to deliver on their promises [8]